(Date:5/16/2008)... - Gefitinib, the once-promising drug formerly app...also known as Iressa, enhanced the effectiveness o...ypes of metastatic breast cancer, according to a P...niversity of Texas M. D. Anderson Cancer Center. ,... first positive study for Iressa in breast cancer,...
(Date:5/16/2008)...ounces appointment of Nomura Code Securities Limit... broker, NEW YORK, May 16 /PRNewswire-FirstCall/ ...estments, Inc. (Amex: MGT ) (the "Company"), and ...Aided Detection (CAD) and,image analysis software ...,of disease, today announced the appointment of NM...
(Date:5/16/2008)...it Portland to Rally Residents to Eat Right, Move ...ts, PORTLAND, Ore., May 16 /PRNewswire/ -- The la...ifferent fad diets -- which seem to go in and out,...ong-term success has been,slim. Two out of three A...ents -- remain overweight or obese., A new campai...
(Date:5/16/2008)...of two proteins in mammalian embryos prevents the ...earchers at the Medical College of Wisconsin, Milw...the May 15 issue of Developmental Biology, was led...gy, neurobiology and anatomy at the Medical Colleg...ly identified the factors responsible for the onse...
Breaking Medicine News(10 mins):Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 2Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 3Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 3Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Medical College of Wisconsin researchers identify proteins that help develop mammalian hearts 2(Date:5/15/2008)... BASEL, Switzerland, May 15 /- Patie...orld,s most common cancers, can expect,further tre...Herceptin(R),(trastuzumab) following new data that...f Clinical Oncology (ASCO) annual meeting in Chica...s will attend the meeting which,is the premier eve...
(Date:5/15/2008)...Phase II Data Presented at ASCO Showed Acceptable ...ce of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N...emotherapeutic agent eribulin mesylate (E7389) dem...ion of women with locally advanced or metastatic,b...er Phase II clinical,trial. The study also suggest...
(Date:5/15/2008)...ood pressure reductions demonstrated in Blacks, Hi...etes and Obese Individuals, PARSIPPANY, N.J., May...d today that data presented at the American Societ...c Meeting (ASH 2008) in New,Orleans demonstrated t...pine and olmesartan medoxomil) safely and effectiv...
(Date:5/15/2008)... APPENZELL, Switzerland, May 15 /- E...es Food and Drug Administration (FDA) has,granted ...ment of pulmonary,arterial hypertension (PAH). Ter...ivotal Phase II trial in Europe., "The FDA,s gran...encourages and strengthens our development program...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Healthcare Crisis Brought to Life in New TV Show 11337 1Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 1Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 2Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 3CorVel to Present at UBS Global Healthcare Services Conference 11332 1CorVel to Present at UBS Global Healthcare Services Conference 11332 2Gene Plays Jekyll and Hyde Role in Deadly Brain Cancer 11331 1...--Mar 19, 2007 - Nymox,Pharmaceutical Corporation ...om its newly completed long-term outcome study of ... clinical trial sites,across the U.S. and 116 unse...bo controlled study., The study assessed symptom s...207 treatment. Overall, without further NX-1207,tr...
...ata on XIENCE V Everolimus,Eluting Coronary Sten... from the ABSORB Bioabsorbable Stent Clinical Stud...-FirstCall/ --,Abbott will present data from sev... and pipeline during a number of late-breaking,c...logy,s 56th,Annual Scientific Session being held...
Other Medicine Technology:Nymox Announces Positive Results from Newly Completed Long-term,Study of NX-1207 for Benign Prostatic Hyperplasia 2Nymox Announces Positive Results from Newly Completed Long-term,Study of NX-1207 for Benign Prostatic Hyperplasia 3Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 2Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 3Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 4Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 5... value in high performance electronic pipetting!, ...design reduce hand fatigue and strain , Stress-fre...r coding for easy volume identification , Accepts ...lton AdvanTip Low Retention and AdvanTip Precision...
The Finnpipette BioControl multichannel has the same innovative features as the single channel model.The same universal handle fits all seven multichannel and five single channel tip cone modules. Bo
...s ideal for all liquid handling applications in th...cally-placed operating buttons, and various dispen...erse pipetting and diluting make this a lab favori... a manual pipette without any adverse effects on t...
...vus is so user-friendly that you'll learn how to u...stantly familiar menu and simple button layout, yo...quickly and easily. The large, clear display is ea...ns. The easily accessible two level menu offers t...
Medicine Products: